AllayJ.A., SleepS.E., LongS.et al.2011. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum. Gene Ther., 22:595–604.
2.
HauckB., MurphyS.L., SmithP.H.et al.2009. Undetectable transcription of cap in a clinical AAV vector: Implications for pre-formed capsid in immune responses. Mol. Ther., 17:144–152.
3.
JayandharanG.R., ZhongL., LiB.et al.2008. Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther., 15:1287–1293.
4.
LuH., QuG., YangX.et al.2011. Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver. Hum. Gene Ther., 22:625–632.
5.
MannoC.S., PierceG.F., ArrudaV.et al.2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.
6.
MingozziF., HasbrouckN.C., Basner-TschakarjanE.et al.2007. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 110:2334–2341.
7.
Montenegro-MirandaP., Ten BloemendaalL., KunneC.et al.2011. Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. Hum. Gene Ther., 22:605–612.
8.
NathwaniA., TuddenhamE., RosalesC.et al.2010. Early clinical trial results following administration of a low dose of a novel self complementary adeno associated viral vector encoding human factor IX in two subjects with severe hemophilia B. Blood, 116:114.
9.
QiaoC., WangB., ZhuX.et al.2002. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol., 76:13015–13027.
10.
SrivastavaA., MaW., LiB.et al.2011. A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Hum. Gene Ther., 22:633–640.
11.
YuanZ., QiaoC., HuP.et al.2011. A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes. Hum Gene Ther., 22:613–624.
